SPRINT reduced cardiovascular events—not aging itself

The bottom line

During randomized follow-up, SPRINT's primary cardiovascular outcome occurred at 1.77% per year with intensive treatment and 2.40% per year with standard treatment, a hazard ratio of 0.73. All-cause mortality was 1.06% versus 1.41% per year, a hazard ratio of 0.75. (Final SPRINT report)

Those are meaningful disease and mortality findings in a defined high-risk population. They are not evidence that intensive treatment slows biological aging, preserves every aspect of function, or extends maximum human lifespan.

Why this matters

High blood pressure is common with age and is a major modifiable cardiovascular risk. SPRINT directly tested two treatment targets rather than merely observing that lower pressure tracks with better health. The distinction matters: a treatment strategy can lower some events while also creating harms, and a population-average result cannot choose an individual's target.

What researchers did

SPRINT randomized 9,361 adults aged 50 or older who had elevated cardiovascular risk and systolic pressure of 130–180 mm Hg. It excluded people with diabetes, prior stroke, symptomatic heart failure, nursing-home residence and several other conditions. The intensive group targeted less than 120 mm Hg; the standard group targeted less than 140 mm Hg, using standardized automated office measurements and more medication on average.

The intervention stopped early after a median 3.26 years because the cardiovascular and mortality boundary favored intensive treatment. The final report followed outcomes beyond that decision. SPRINT MIND separately studied probable dementia and mild cognitive impairment; a later cognitive report observed participants after the randomized treatment period rather than creating a new randomized comparison.

What they found

The primary cardiovascular composite and all-cause mortality were lower with intensive treatment. Absolute rates provide the clearest scale: the primary outcome differed by 0.63 percentage points per year and mortality by 0.35 percentage points per year during the reported period.

Serious hypotension occurred in 99 intensive-treatment participants (2.1%) and 58 standard-treatment participants (1.2%). Serious electrolyte abnormalities occurred in 138 (2.9%) versus 104 (2.2%); acute kidney injury or kidney failure in 193 (4.1%) versus 115 (2.5%). Injurious falls were nearly identical: 102 versus 101.

In SPRINT MIND, probable dementia occurred in 149 versus 176 participants, hazard ratio 0.83 with a 95% confidence interval of 0.67–1.04—not statistically significant. Mild cognitive impairment, a secondary result, occurred in 287 versus 353 participants, hazard ratio 0.81. These are separate outcomes and should not be summarized as “SPRINT prevented dementia.” (SPRINT MIND)

How strong is the evidence?

The cardiovascular and serious-adverse-event evidence is strong: SPRINT was large, randomized, multicenter and stopped under a prespecified monitoring process. Open-label treatment, early stopping, intensive measurement procedures and selective eligibility still limit translation to routine care.

The cognitive picture is less settled. Probable dementia was the main dementia outcome and was null; mild cognitive impairment was secondary. Extended follow-up may be informative, but treatment after the randomized phase could differ and causal certainty is lower.

What this study does not show

SPRINT does not define a safe target for every person, prove that lower is always better, or support changing medication without clinical supervision. It did not enroll people with diabetes or prior stroke and does not establish the same balance in frail, institutionalized or otherwise excluded populations.

It did not show slower biological aging, universal preservation of physical or cognitive function, longer healthspan, or longer lifespan. Lower all-cause mortality during trial follow-up is an important clinical outcome, but it is not the same claim as changing the human aging process.

Safety and conflicts

The trial's benefit came with more serious hypotension, electrolyte problems and acute kidney injury or failure. Falls were not higher in the reported serious-adverse-event table. These group averages do not predict an individual's medication tolerance, kidney risk, orthostatic symptoms or competing priorities.

SPRINT was sponsored by the National Heart, Lung, and Blood Institute with support from other NIH institutes and US federal agencies. The final report lists investigator disclosures and supplied medications; readers should use the full disclosure statement for author-level details.

What happens next

Clinical guidance continues to integrate SPRINT with other trials, home and office measurement differences, comorbidity, frailty and patient priorities. Longer cognitive follow-up can refine—but not retroactively rewrite—the randomized dementia result. Future work should keep cardiovascular events, kidney effects, falls, cognition, daily function and lifespan as separate outcomes.